Viatris, Inc. ( (VTRS) ) has released its Q3 earnings. Here is a breakdown of the information Viatris, Inc. presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Viatris Inc. is a global healthcare company engaged in providing access to high-quality medicines and bridging the gap between generics and brand-name pharmaceuticals. The company delivers medications to approximately 1 billion patients worldwide annually. In its third-quarter earnings report for 2024, Viatris Inc. declared total revenues of $3.8 billion, marking a 3% growth on a divestiture-adjusted basis. The company achieved $133 million in new product revenues and repaid approximately $1.9 billion of debt, reinforcing its financial steadiness. Key financial metrics for Viatris include U.S. GAAP net earnings of $95 million and adjusted EBITDA of $1.3 billion, reflecting an increase of 4% on a divestiture-adjusted basis. The adjusted EPS rose by 6% to $0.75 per share. Strategic moves include an exclusive licensing agreement for Sotagliflozin, which augments its cardiovascular portfolio. Looking ahead, Viatris reaffirms its full-year 2024 outlook, anticipating revenue growth of about 2% on a divestiture-adjusted operational basis, as the company continues to focus on capital allocation and shareholder value optimization.
